---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-115554"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:17:35.174098+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vor Bio winds down operations, cuts 95% of staff, and explores sale or merger

## Summary
- Board approved wind-down of clinical and manufacturing operations; workforce reduced by 147 employees (~95%).
- Total wind-down cost estimated at $19.3M including $10.9M in severance and $4.4M asset write-down.
- CFO Han Choi and CSO Tirtha Chakraborty terminated without cause effective May 16, 2025; severance of ten months salary.
- Company exploring strategic alternatives including asset sale, licensing, merger, or sale of the company.
- Cash, cash equivalents and marketable securities were $91.9M as of Dec 31, 2024; Q1 results due May 14.

## SEC filing metadata
- accession: 0001193125-25-115554
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312525115554/0001193125-25-115554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312525115554/d924194d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-115554
- JSON: https://secwatch.observer/filing/0001193125-25-115554.json
- Plain text: https://secwatch.observer/filing/0001193125-25-115554.txt

## Key facts
- Executive change
  Han Choi was terminated as Chief Financial Officer at Vor Biopharma Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312525115554/0001193125-25-115554-index.htm
- Executive change
  Tirtha Chakraborty was terminated as Chief Scientific Officer and Head of Technical Operations at Vor Biopharma Inc..
  - Action: terminated
  - Role: Chief Scientific Officer and Head of Technical Operations
  source text: on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312525115554/0001193125-25-115554-index.htm
- Restructurings & Charges
  Vor Biopharma Inc. announced a restructuring with charges of approximately $19.3 million affecting clinical and manufacturing operations (147 full-time employees, or approximately 95% of the Company’s current employee base).
  - Type: restructuring
  - Charge: approximately $19.3 million
  - Affected area: clinical and manufacturing operations
  - Headcount: 147 full-time employees, or approximately 95% of the Company’s current employee base
  source text: full-time employees, or approximately 95% of the Company’s current employee base (the “Wind Down”). The total costs related to the Wind Down are estimated to be approximately $19.3 million. The Company estimates that it will incur approximately $3.5 million in contract termination and other costs related to the discontinuation of its clinical trials, approximately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312525115554/0001193125-25-115554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.